Market Place
Sourcing Support
Immuron CEO Present to 21st Virtual Investor Summit Microcap
21 Nov 2024 //
GLOBENEWSWIRE
Immuron CEO Steven Lydeamore Participates In Healthcare Conference
16 Oct 2024 //
GLOBENEWSWIRE
Immuron Travelan® continued strong sales growth
15 Oct 2024 //
GLOBENEWSWIRE
NMRC Reports Results For Campylobacter Infection Model Study
04 Oct 2024 //
GLOBENEWSWIRE
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
05 Sep 2024 //
GLOBENEWSWIRE
Immuron Announces New U.S. Defense Award For Travelan® Research Advancement
16 Aug 2024 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
15 Aug 2024 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
07 Aug 2024 //
GLOBENEWSWIRE
Immuron announces record Travelan® sales globally, Australia and USA
15 Jul 2024 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
05 Jun 2024 //
GLOBENEWSWIRE
Immuron Board Changes
31 May 2024 //
GLOBENEWSWIRE
Immuron CEO Steven Lydeamore to present at Peak Sky High
31 May 2024 //
GLOBENEWSWIRE
Immuron Limited to Present at the Emerging Growth Conference
07 May 2024 //
GLOBENEWSWIRE
Immuron Director Resignation
03 May 2024 //
GLOBENEWSWIRE
Immunron To Host Virtual Event
15 Apr 2024 //
GLOBENEWSWIRE
Immuron Travelan® sales continued strong growth
10 Apr 2024 //
GLOBENEWSWIRE
Immuron Announces Positive Results Support Travelan
07 Mar 2024 //
GLOBENEWSWIRE
Immuron Presentation Australian Biologics Festival 2024
21 Feb 2024 //
GLOBENEWSWIRE
Immuron achieves record Travelan® sales
13 Feb 2024 //
GLOBENEWSWIRE
Immuron achieves record half yearly Travelan® sales
16 Jan 2024 //
GLOBENEWSWIRE
Immuron Clinical Trials Update
22 Dec 2023 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
28 Nov 2023 //
GLOBENEWSWIRE
Immuron CEO Steven Lydeamore Investor Webinar Presentation
13 Nov 2023 //
GLOBENEWSWIRE
Immuron CEO Steven Lydeamore presented at AusBioInvest
30 Oct 2023 //
GLOBENEWSWIRE
Immuron Announces Travelan® Clinical Study Cohort 2 commences
18 Oct 2023 //
GLOBENEWSWIRE
Immuron achieves record quarterly Travelan® sales
11 Oct 2023 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
11 Sep 2023 //
GLOBENEWSWIRE
Immuron to present at the Military Health System Research Symposium
14 Aug 2023 //
GLOBENEWSWIRE
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
25 Jul 2023 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to present at Bioshares
24 Jul 2023 //
GLOBENEWSWIRE
Immuron Business Update - Ateria Health launches Juvia„¢ in Australia
11 Jul 2023 //
GLOBENEWSWIRE
Immuron FY23 Sales increase 136% on FY22 Sales
05 Jul 2023 //
GLOBENEWSWIRE
Immuron Chairman Transition
30 Jun 2023 //
GLOBENEWSWIRE
Immuron Initiates Recruitment of Travelan® Clinical Study
30 May 2023 //
GLOBENEWSWIRE
Immuron Announces FDA Removed Hold on New Campylobacter ETEC Therapeutic
08 May 2023 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
02 May 2023 //
GLOBENEWSWIRE
Immuron Q3 FY23 Business Update Presentation
19 Apr 2023 //
GLOBENEWSWIRE
Q3 FY23 Business Update Webinar Notification
11 Apr 2023 //
GLOBENEWSWIRE
Immuron Q3 Sales reach 150% of 1H Sales
06 Apr 2023 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to host an investor webinar
15 Feb 2023 //
GLOBENEWSWIRE
Immuron US DoD NMRC responds to FDA Hold for Campylobacter ETEC Therapeutic
25 Jan 2023 //
GLOBENEWSWIRE
Immuron Receives European Patent on Drug Composition
17 Jan 2023 //
GLOBENEWSWIRE
Immuron Receives FDA Approval for Travelan IND Application
23 Dec 2022 //
GLOBENEWSWIRE
Immuron completes strategic investment in leading gut health biotech Ateria
16 Nov 2022 //
GLOBENEWSWIRE
Immuron CEO, Steven Lydeamore to present at AusBioInvest
26 Oct 2022 //
GLOBENEWSWIRE
Immuron strategic investment in leading gut health biotech Ateria Health
13 Oct 2022 //
GLOBENEWSWIRE
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
04 Oct 2022 //
GLOBENEWSWIRE
Immuron culls COVID drug as variants, competition hit prospects
20 Aug 2022 //
FIERCEBIOTECH
Immuron US DoD Naval Medical Research Center Receives feedback on IND Appln.
26 Jul 2022 //
GLOBENEWSWIRE
Immuron North American Travelan Sales up 494% and Global sales up 431%
11 Jul 2022 //
GLOBENEWSWIRE
Immuron Receives EU Patent Notification on Drug Composition in C. difficile
07 Jul 2022 //
GLOBENEWSWIRE
Immuron Submits IND Application for New Campylobacter ETEC Therapeutic
11 May 2022 //
GLOBENEWSWIRE
Immuron appoints Steven Lydeamore as Chief Executive Officer
06 May 2022 //
BIOSPECTRUMASIA
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer
05 May 2022 //
GLOBENEWSWIRE
Immuron Travelan Global sales up 216%
27 Apr 2022 //
GLOBENEWSWIRE
Immuron new MTEC project proposal Development of Oral Immunotherapy
19 Apr 2022 //
GLOBENEWSWIRE
Immuron Receives AUD $306,154 R&D Tax Concession Refund
17 Jan 2022 //
GLOBENEWSWIRE
Immuron Receives EU Patent on Drug Composition to Treat Travelers’ Diarrhea
13 Jan 2022 //
GLOBENEWSWIRE
Immuron Receives EU Patent on Drug Composition to Treat Travelers’ Diarrhea
12 Jan 2022 //
BIOSPACE
Immuron planned Acquisition of R&D Vaccine Company
23 Sep 2021 //
GLOBENEWSWIRE
